Northwest Biotherapeutics reported $1.61B in Ordinary Share Capital for its fiscal quarter ending in March of 2026.





Ordinary Share Capital Change Date
Agenus USD 38.52M 3.2M Mar/2026
AstraZeneca USD 1.55B 44K Jun/2026
Bristol-Myers Squibb USD 2.04B 1.74B Sep/2025
Celldex Therapeutics USD 78.5M 11.93M Jun/2026
Eisai JPY 282.46M 345K Jun/2026
Merck USD 2.47B 4.93M Mar/2026
Northwest Biotherapeutics USD 1.61B 88.6M Mar/2026
Pfizer USD 5.7B 0 Jun/2026
Plus Therapeutics USD 275K 138.4M Mar/2026
Roche Holding CHF 796.77M 1.15M Jun/2026